An increasing number of cancer clinical trials are conducted in low-and-middle-income countries (LMICs). Increasing the representation of LMICs in cancer drug trials is encouraging, but we are concerned about research parasitism and parachutism in these practices. In this commentary, we explore how LMICs may not have been served by participating in these global cancer drug trials.